Literature DB >> 15165363

A molecular basis for the efficacy of magnesium treatment following traumatic brain injury in rats.

Jin Suk Lee1, Young Min Han, Do Sung Yoo, Seung Jin Choi, Byung Hyune Choi, Jong Hyun Kim, Young Hoon Kim, Pil Woo Huh, Young Jin Ko, Hyoung Kyun Rha, Kyung Suck Cho, Dal Soo Kim.   

Abstract

Magnesium ions have been shown to be a promising treatment for brain lesions caused by traumatic brain injury (TBI), as well as for the associated acute neurodegeneration and progressive functional deficits. This study investigated the effects of magnesium on the expression of the cell death/survival related proteins following TBI. Male Sprague-Dawley (SD) rats (n = 66, 280-320 g body weight) were subjected to sham surgery alone (n = 14), or to the surgery followed by a lateral fluid percussion brain injury of moderate severity (n = 52, 2.4-2.7 atm). The injured rats were randomly treated with an intravenous bolus of magnesium chloride (n = 26, 125 micromol) or saline vehicle (n = 26). The coronal brain sections were quantitatively analyzed for cell apoptosis and the expression of p53-related proteins, Bcl-2, cyclin D1 and PCNA at 1, 2, and 4 days post-injury by immunohistochemistry or in situ hybridization. Tissue damage was observed primarily in the ipsilateral cortex of the injured region with the induction of apoptosis and p53 mRNA level at 2 days after TBI. The expression of p53 and responding proteins (p21(WAF1/CIP1), Mdm2 and Bax) showed a temporal pattern similar to the apoptotic events in the time course experiments. They were induced in the early time points of days 1-2, decreasing by day 4 after TBI. In contrast, the expression of the cell survival related proteins - Bcl-2, cyclin D1, and PCNA - was most significant at day 4 post-injury, when the rate of apoptosis decreased. Magnesium treatment resulted in a reduction in apoptosis and expression of p53-related proteins. However, it had only a slight additive effect on the expression of the survival related proteins in the same time-course. These results provide a molecular basis for the efficiency of magnesium in treating TBI-induced tissue damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15165363     DOI: 10.1089/089771504774129883

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  7 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 3.  Use of magnesium in traumatic brain injury.

Authors:  Ananda P Sen; Anil Gulati
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

4.  Intravenous infusion of magnesium chloride improves epicenter blood flow during the acute stage of contusive spinal cord injury in rats.

Authors:  Johongir M Muradov; Theo Hagg
Journal:  J Neurotrauma       Date:  2013-05-09       Impact factor: 5.269

5.  Initial Serum Magnesium Level Is Associated with Mortality Risk in Traumatic Brain Injury Patients.

Authors:  Ruoran Wang; Min He; Jianguo Xu
Journal:  Nutrients       Date:  2022-10-07       Impact factor: 6.706

6.  Effects of Vitamin C and Magnesium L-threonate Treatment on Learning and Memory in Lead-poisoned Mice.

Authors:  Kemajl Bislimi; Ilir Mazreku; Jeton Halili; Valbona Aliko; Kushtrim Sinani; Liridon Hoxha
Journal:  J Vet Res       Date:  2021-06-08       Impact factor: 1.744

7.  Serum Magnesium as a Marker of Neurological Outcome in Severe Traumatic Brain Injury Patients.

Authors:  Raghavendra Nayak; Sanjeev Attry; Samarendra Nath Ghosh
Journal:  Asian J Neurosurg       Date:  2018 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.